JPS5825980B2 - サイクリックヌクレオチドの定量法 - Google Patents
サイクリックヌクレオチドの定量法Info
- Publication number
- JPS5825980B2 JPS5825980B2 JP51014665A JP1466576A JPS5825980B2 JP S5825980 B2 JPS5825980 B2 JP S5825980B2 JP 51014665 A JP51014665 A JP 51014665A JP 1466576 A JP1466576 A JP 1466576A JP S5825980 B2 JPS5825980 B2 JP S5825980B2
- Authority
- JP
- Japan
- Prior art keywords
- cyclic
- antibody
- biological sample
- guanylate
- camp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 39
- 125000004122 cyclic group Chemical group 0.000 title claims description 20
- 238000011002 quantification Methods 0.000 title description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 54
- 238000010613 succinylation reaction Methods 0.000 claims description 37
- 239000012472 biological sample Substances 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 26
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 23
- 239000000872 buffer Substances 0.000 claims description 23
- 229940014800 succinic anhydride Drugs 0.000 claims description 23
- 239000003153 chemical reaction reagent Substances 0.000 claims description 20
- 239000012086 standard solution Substances 0.000 claims description 20
- 230000035322 succinylation Effects 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 18
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 claims description 16
- 239000003960 organic solvent Substances 0.000 claims description 14
- 230000002285 radioactive effect Effects 0.000 claims description 13
- 150000003512 tertiary amines Chemical class 0.000 claims description 13
- 239000013024 dilution buffer Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- 239000011630 iodine Substances 0.000 claims description 7
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims description 6
- 235000013928 guanylic acid Nutrition 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- MWZPENIJLUWBSY-VIFPVBQESA-N methyl L-tyrosinate Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWZPENIJLUWBSY-VIFPVBQESA-N 0.000 claims description 6
- 239000004226 guanylic acid Substances 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 3
- 239000011550 stock solution Substances 0.000 claims description 3
- 229950006790 adenosine phosphate Drugs 0.000 claims description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims 7
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 41
- 239000000523 sample Substances 0.000 description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 238000005259 measurement Methods 0.000 description 17
- 238000012360 testing method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000003127 radioimmunoassay Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- XLLIQLLCWZCATF-UHFFFAOYSA-N 2-methoxyethyl acetate Chemical compound COCCOC(C)=O XLLIQLLCWZCATF-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000005485 Thrombocytosis Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- STDZGEMKEIYXRQ-UHFFFAOYSA-N O1CCOCC1.C1(CCC(=O)O1)=O Chemical compound O1CCOCC1.C1(CCC(=O)O1)=O STDZGEMKEIYXRQ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000006078 pseudohypoparathyroidism Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- ISPBABGJNLPGOY-UHFFFAOYSA-K zinc barium(2+) hydroxide sulfate Chemical compound [OH-].[Zn+2].[Ba+2].[O-]S([O-])(=O)=O ISPBABGJNLPGOY-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/826—Additives, e.g. buffers, diluents, preservatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP51014665A JPS5825980B2 (ja) | 1976-02-12 | 1976-02-12 | サイクリックヌクレオチドの定量法 |
| US05/766,509 US4115538A (en) | 1976-02-12 | 1977-02-07 | Assay kit for cAMP and/or cGMP and method of using the same |
| GB4909/77A GB1527465A (en) | 1976-02-12 | 1977-02-07 | Assay kit for camp and/or cgmp and method for using the same |
| CH161277A CH618015A5 (enExample) | 1976-02-12 | 1977-02-10 | |
| FR7703742A FR2341139A1 (fr) | 1976-02-12 | 1977-02-10 | Trousse de reactifs pour le dosage de l'adenosine-3', 5'-monophosphate cyclique et du guanosine-3', 5'-monophosphate cyclique |
| DE2705897A DE2705897C3 (de) | 1976-02-12 | 1977-02-11 | Verfahren zur radioimmunologischen Bestimmung von cyclischem Adenosin-3', 5'-monophosphat und/oder cyclischem Guanosin-3'3'-monophosphat |
| CA271,566A CA1092022A (en) | 1976-02-12 | 1977-02-11 | Assay kit for camp and/or cgmp and method of using the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP51014665A JPS5825980B2 (ja) | 1976-02-12 | 1976-02-12 | サイクリックヌクレオチドの定量法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4767877A Division JPS5318724A (en) | 1977-04-23 | 1977-04-23 | Determination of cyclic nucleotides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS52117418A JPS52117418A (en) | 1977-10-01 |
| JPS5825980B2 true JPS5825980B2 (ja) | 1983-05-31 |
Family
ID=11867499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51014665A Expired JPS5825980B2 (ja) | 1976-02-12 | 1976-02-12 | サイクリックヌクレオチドの定量法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4115538A (enExample) |
| JP (1) | JPS5825980B2 (enExample) |
| CA (1) | CA1092022A (enExample) |
| CH (1) | CH618015A5 (enExample) |
| DE (1) | DE2705897C3 (enExample) |
| FR (1) | FR2341139A1 (enExample) |
| GB (1) | GB1527465A (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4378344A (en) * | 1979-09-28 | 1983-03-29 | Ventrex Laboratories, Inc. | Method and apparatus for performing multiple, simultaneous in vitro diagnostic tests using a solid phase system |
| US4433061A (en) * | 1981-06-01 | 1984-02-21 | American Hospital Supply Corporation | Radioimmunoassay for cyclic nucleotides |
| JPS5811857A (ja) * | 1981-07-15 | 1983-01-22 | Yamasa Shoyu Co Ltd | アデノシンの定量法 |
| US5118607A (en) * | 1989-10-23 | 1992-06-02 | Hawaii Biotechnology Group, Inc. | Non-aqueous solvent specific binding protein assays |
| CA2238283C (en) * | 1997-05-30 | 2002-08-20 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
| US7402400B2 (en) | 2001-07-03 | 2008-07-22 | Regents Of The University Of California | Mammalian sweet taste receptors |
| US6686171B2 (en) | 1999-05-10 | 2004-02-03 | Tropix, Inc. | Competitive chemiluminescent assay for cyclic nucleotide monophosphates |
| US6794156B2 (en) | 1999-05-10 | 2004-09-21 | Applera Corporation | Cell growth, induction and lysis in an antibody-coated microplate for use in an ELISA |
| TW201006846A (en) | 2000-03-07 | 2010-02-16 | Senomyx Inc | T1R taste receptor and genes encidung same |
| TW201022287A (en) | 2001-01-03 | 2010-06-16 | Senomyx Inc | T1R taste receptors and genes encoding same |
| US7883856B2 (en) | 2001-04-05 | 2011-02-08 | Senomyx Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
| CA2445197A1 (en) * | 2001-04-20 | 2002-10-31 | Mount Sinai School Of Medicine | T1r3 a novel taste receptor |
| US7803982B2 (en) | 2001-04-20 | 2010-09-28 | The Mount Sinai School Of Medicine Of New York University | T1R3 transgenic animals, cells and related methods |
| US20070135425A1 (en) * | 2001-05-04 | 2007-06-14 | Amgen Inc. | Fused heterocyclic compounds |
| US6809104B2 (en) * | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
| WO2003001876A2 (en) | 2001-06-26 | 2003-01-09 | Senomyx, Inc. | T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds |
| CA2463553A1 (en) * | 2001-10-12 | 2003-04-17 | The Regents Of The University Of California | Gastrointestinal chemosensory receptors |
| EA009421B1 (ru) * | 2002-11-06 | 2007-12-28 | Эмджен Инк. | Конденсированные гетероциклические соединения |
| SG145745A1 (en) | 2003-08-06 | 2008-09-29 | Senomyx Inc | Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof |
| US20050244810A1 (en) * | 2003-09-29 | 2005-11-03 | Egan Josephine M | Taste signaling in gastrointestinal cells |
| EP1937718B1 (en) | 2005-10-20 | 2017-12-06 | Senomyx, Inc. | Chimeric human sweet-umami and umami-sweet taste receptors |
| WO2007121604A2 (en) | 2006-04-20 | 2007-11-01 | Givaudan Sa | Method relating to sweetness enhancement |
| JP2009533065A (ja) * | 2006-04-20 | 2009-09-17 | ジボダン エス エー | 味覚物質同定のための機能的方法 |
| US20110097741A1 (en) * | 2006-04-20 | 2011-04-28 | Jay Patrick Slack | Partial t1r2 nucleic acid sequence, receptor protein and its use in screening assays |
| EP2010009B1 (en) | 2006-04-21 | 2017-06-14 | Senomyx, Inc. | Processes for preparing solid flavorant compositions |
| US8039233B2 (en) * | 2007-01-18 | 2011-10-18 | Givaudan S.A. | Nucleic acid sequences and their use in methods to identify umami modulatiors |
| WO2008119195A1 (en) | 2007-03-30 | 2008-10-09 | Givaudan Sa | Methods to identify modulators |
| CN101784281B (zh) | 2007-08-01 | 2014-07-02 | 总医院有限公司 | 确定g蛋白偶联受体激动剂的方法 |
| HUE025137T2 (en) | 2007-08-21 | 2016-01-28 | Senomyx Inc | Compositions are bitter taste blocking (blocking) compounds |
| US9115386B2 (en) | 2008-09-26 | 2015-08-25 | Children's Medical Center Corporation | Selective oxidation of 5-methylcytosine by TET-family proteins |
| CN102333536B (zh) | 2008-12-29 | 2014-08-13 | 特维那公司 | β-抑制蛋白效应器和组合物以及其应用方法 |
| CN102481276A (zh) | 2009-04-20 | 2012-05-30 | 埃尔舍利克斯治疗公司 | 基于化学感受受体配体的治疗法 |
| US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
| US8828953B2 (en) * | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| EP2567231A1 (en) | 2010-05-07 | 2013-03-13 | Givaudan SA | Methods to identify modulators of tas2r4s receptors |
| US20130115624A1 (en) | 2010-05-07 | 2013-05-09 | Givaudan S.A. | Methods To Identify Modulators |
| CN104220875A (zh) | 2010-10-19 | 2014-12-17 | 埃尔舍利克斯治疗公司 | 基于化学感应受体配体的治疗 |
| SG191855A1 (en) | 2011-01-07 | 2013-08-30 | Elcelyx Therapeutics Inc | Chemosensory receptor ligand-based therapies |
| WO2012129495A1 (en) | 2011-03-23 | 2012-09-27 | Trevena, Inc. | Opioid receptor ligands and methods of using and making same |
| US20130040317A1 (en) | 2011-08-08 | 2013-02-14 | The University Of North Carolina At Chapel Hill | Cell lines comprising endogenous taste receptors and their uses |
| EP2742350B1 (en) | 2011-08-08 | 2019-10-30 | The Coca-Cola Company | Cell lines comprising endogenous taste receptors and their uses |
| CA2862933A1 (en) | 2012-01-31 | 2013-08-08 | Trevena, Inc. | .beta.-arrestin effectors and compositions and methods of use thereof |
| WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| NZ710444A (en) | 2013-02-11 | 2020-08-28 | Univ California | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy |
| EP2983507B1 (en) | 2013-03-15 | 2020-04-22 | Applied Food Biotechnology, Inc. | Feline bitter taste receptors and methods |
| EP3102223A4 (en) | 2014-02-07 | 2017-11-29 | Trevena, Inc. | Crystalline and amorphous forms of a beta-arrestin effector |
| WO2015123365A1 (en) | 2014-02-11 | 2015-08-20 | Mitokinin Llc | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
| CA2948858A1 (en) | 2014-05-19 | 2015-11-26 | Trevena, Inc. | Synthesis of beta-arrestin effectors |
| PL3344248T3 (pl) | 2015-09-02 | 2022-07-18 | Trevena, Inc. | Zawierające sześcioczłonowy aza-heterocykl związki modulujące receptor opioidowy delta oraz sposoby ich wykorzystywania i wytwarzania |
| CA3007020A1 (en) | 2015-12-14 | 2017-06-22 | Trevena, Inc. | Methods of treating hyperalgesia |
| US20190178889A1 (en) * | 2016-09-05 | 2019-06-13 | BellBrook Labs | High-throughput screening assay |
| KR102662065B1 (ko) | 2017-02-17 | 2024-05-07 | 트레베나, 인코포레이티드. | 7-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법 |
| KR20190129867A (ko) | 2017-02-17 | 2019-11-20 | 트레베나, 인코포레이티드. | 5-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법 |
| CA3067695A1 (en) | 2017-06-21 | 2018-12-27 | Mitokinin, Inc. | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
| CN112858504A (zh) * | 2021-01-08 | 2021-05-28 | 苏州国辰生物科技股份有限公司 | 一种液质联用测定生物体液样品中cGMP浓度的检测方法 |
| WO2023154597A1 (en) | 2022-02-11 | 2023-08-17 | Firmenich Incorporated | Cells expressing umami taste receptors and uses thereof |
-
1976
- 1976-02-12 JP JP51014665A patent/JPS5825980B2/ja not_active Expired
-
1977
- 1977-02-07 US US05/766,509 patent/US4115538A/en not_active Expired - Lifetime
- 1977-02-07 GB GB4909/77A patent/GB1527465A/en not_active Expired
- 1977-02-10 CH CH161277A patent/CH618015A5/fr not_active IP Right Cessation
- 1977-02-10 FR FR7703742A patent/FR2341139A1/fr active Granted
- 1977-02-11 CA CA271,566A patent/CA1092022A/en not_active Expired
- 1977-02-11 DE DE2705897A patent/DE2705897C3/de not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2341139A1 (fr) | 1977-09-09 |
| US4115538A (en) | 1978-09-19 |
| GB1527465A (en) | 1978-10-04 |
| CA1092022A (en) | 1980-12-23 |
| DE2705897B2 (de) | 1979-06-21 |
| CH618015A5 (enExample) | 1980-06-30 |
| DE2705897C3 (de) | 1980-02-28 |
| JPS52117418A (en) | 1977-10-01 |
| FR2341139B1 (enExample) | 1979-10-05 |
| DE2705897A1 (de) | 1977-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS5825980B2 (ja) | サイクリックヌクレオチドの定量法 | |
| CN108362688B (zh) | 一种25羟基维生素d磁微粒化学发光检测试剂盒 | |
| JPH04233460A (ja) | タンパク質沈澱試薬 | |
| EP0240021A1 (en) | Fluorescence polarization immunoassay and reagents for use therein | |
| JPS6411148B2 (enExample) | ||
| EP0713096A1 (en) | Immunoassay and kit for insulin-like growth factors | |
| CN110531085A (zh) | 一种测定人体神经丝轻链蛋白含量的磁微粒化学发光检测试剂盒及其制备方法 | |
| JPS5811857A (ja) | アデノシンの定量法 | |
| JPS62253399A (ja) | 脂質結合性シアル酸の測定法 | |
| CN105911298A (zh) | 一种测定肌红蛋白的试剂盒 | |
| CN106093418A (zh) | 一种测定肌钙蛋白i的试剂盒及其制备方法 | |
| US4624916A (en) | Process and composition for the rapid quantitation of small levels of creative kinase-MB isoenzyme | |
| US4731336A (en) | Immunoassay for complement fragments | |
| EP0122620B1 (en) | Reagent and kit for determination of blood coagulation factor xiii | |
| JPS5925184B2 (ja) | 免疫測定法における非特異的阻害作用の除去法 | |
| JP3490715B2 (ja) | ヘモグロビン前進性グルコシル化終末産物の検出方法 | |
| KR102802882B1 (ko) | 혈액 내 유리 스테로이드 측정을 위한 희석용액 및 이를 이용한 스테로이드 측정방법 | |
| DK151400B (da) | Latexreagens sensitiveret med steroid-serumalbumin-konjugat og fremgangsmaade til fremstilling af latexreagenset | |
| JPH08304406A (ja) | カリブレーターマトリックス | |
| JPH0326787B2 (enExample) | ||
| CN109444431A (zh) | 一种心脏肌球蛋白结合蛋白c的定量检测方法及检测试剂盒 | |
| Egan et al. | Radioimmune assay for the diagnosis of human cancer | |
| JP4877578B2 (ja) | 抗原の測定法およびそれに用いるキット | |
| CN112710829A (zh) | 一种新型冠状病毒IgG抗体的元素质谱法检测试剂盒 | |
| US4433061A (en) | Radioimmunoassay for cyclic nucleotides |